Search

At MSK, our goal is not just to train the scientists of tomorrow, but the scientific leaders.

… Monday, September 18, 2023 When Direna Alonso-Curbelo, PhD, was a graduate student in Madrid, she had the opportunity to visit Memorial Sloan Kettering Cancer Center (MSK) for a summer-long internship. That gave her a taste of what it was like to live and breathe science at one of the world’s premier

New research published in The New England Journal of Medicine finds adding the immunotherapy drug pembrolizumab (Keytruda®) to standard chemotherapy greatly improves outcomes in people with advanced endometrial cancer. The phase 3 study was overseen by MSK gynecologic medical oncologist Carol Aghajanian.

… Monday, March 27, 2023 Endometrial cancer , which makes up about 90% of uterine cancers, will be diagnosed in more than 65,000 people in the United States this year. It is the fourth most common cancer in women and is one of the few cancers that is increasing in incidence and mortality. Unfortunately

Memorial Sloan Kettering Cancer Center (MSK) researchers presented breakthrough advances in new treatment approaches for several cancer indications at the 2023 ASCO Annual Meeting held June 2 to 6, 2023. Highlights of practice-changing study results in glioma, rectal cancer, non-small cell lung cancer, biliary tract cancer, and more were as follows:

… Tuesday, June 6, 2023 Memorial Sloan Kettering Cancer Center (MSK) researchers presented breakthrough advances in new treatment approaches for several cancer indications at the 2023 ASCO Annual Meeting held June 2 to 6, 2023. Highlights of practice-changing study results in glioma, rectal cancer, non-small

Learn why some patients are less physically active during and after treatment — plus, some tips from Jun Mao, Chief of the Integrative Medicine Service at MSK.

… Wednesday, January 25, 2017 Summary In a recent survey, 75% of people with cancer said they reduced their physical activity after their diagnosis. We spoke with two experts from the Integrative Medicine Service at MSK to learn more. A new study led by Memorial Sloan Kettering researchers shows that 75%

Physicians and scientists from Memorial Sloan Kettering Cancer Center (MSK) will join oncology experts and members of the global cancer research community to present the latest advances in cancer during The American Society of Hematology (ASH) annual meeting, December 9-12 in San Diego, CA.

… Tuesday, December 5, 2023 Physicians and scientists from Memorial Sloan Kettering Cancer Center (MSK) will join oncology experts and members of the global cancer research community to present the latest advances in cancer during The American Society of Hematology (ASH) annual meeting, December 9-12 in

For those living with advanced cancer, quality of life means pursuing what matters most to each person — whether that’s making art, running marathons, caring for others, or spending more time with family.

… Friday, June 6, 2025 Cancer that spreads from an initial tumor to other parts of the body — known as metastasis — is a daunting diagnosis that brings with it a great deal of fear and uncertainty. While metastatic cancer remains challenging, significant advances in diagnosis and treatment are making it

Overcoming resistance to drug treatment for lung cancer is a critical challenge.

… Thursday, November 29, 2018 Summary Investigators are looking for ways to overcome resistance to drugs that target lung cancer. Lung cancer was one of the first cancers that could be targeted by drugs aimed at specific mutations in tumors. Advances in genomic medicine and the molecular analysis of tumors

Results from the largest study of men with prostate cancer treated with high-dose, intensity modulated radiation therapy (IMRT) show that the majority of patients remain alive with no evidence of disease after an average follow-up period of eight years.

… Wednesday, September 27, 2006 Results from the largest study of men with prostate cancer treated with high-dose, intensity modulated radiation therapy (IMRT) show that the majority of patients remain alive with no evidence of disease after an average follow-up period of eight years. The 561 prostate

Memorial Sloan Kettering attained Magnet recognition for the second time, a testament to our continued dedication to high-quality nursing practice.

… Wednesday, November 25, 2020 VIDEO | 03:09 2020 MSK Nurses Magnet Recognition Video Details On November 23, 2020, Memorial Sloan Kettering (MSK) attained Magnet recognition for the second time, a testament to our continued dedication to high-quality nursing practice. The American Nurses Credentialing

Unlike the clinical management of other types of cancer, a multidisciplinary approach is not the established norm for treating skin cancer, resulting in significantly limited opportunities to individualize patient care.

… Thursday, June 14, 2018 Unlike the clinical management of other types of cancer, a multidisciplinary approach is not the established norm for treating skin cancer, resulting in significantly limited opportunities to individualize patient care. A recent study by our group, and set to be published in the